White Paper
The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models—inbred mice bearing an engrafted tumor derived from a genetically identical mouse strain—are invaluable preclinical research tools that enable tumor studies in the context of a complete and functional immune system. These models are powerful tools for studying tumor-immune system interactions and investigation into new immunotherapies.
Taconic Biosciences is a global leader in genetically engineered mouse models and colony management services. We support researchers in advancing their science with innovative, reliable solutions. Learn More about our Fully Integrated Custom Model Generation and Colony Management Solutions.
Caroline Horizny Mitchell, PhD has experience in molecular biology research, creating compelling scientific content, and developing marketing strategies. Caroline has experience in scientific writing, content creation, and RNA biology and nanotechnology. She obtained her B.S. and M.S. in biology from Rensselaer Polytechnic Institute and Ph.D. in Nanoscale Science from the University at Albany.
Director, Global Application Sciences
Philip Dubé, PhD has special expertise in rodent models of inflammatory bowel disease (IBD) and has 18+ years’ experience in rodent model use. He is the Director of Global Application Sciences at Taconic. He completed research fellowships at Vanderbilt University and Children’s Hospital Los Angeles, and served as an Institutional Animal Care and Use Committee member. He holds a Ph.D. in physiology and an Honor’s B.Sc. in pharmacology from the University of Toronto.
